Ambu A/S (OTCMKTS:AMBBY) & Avita Medical (NASDAQ:RCEL) Head to Head Analysis

Ambu A/S (OTCMKTS:AMBBY) and Avita Medical (NASDAQ:RCEL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Valuation & Earnings

This table compares Ambu A/S and Avita Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ambu A/S	$894.37 million	2.89	$90.19 million	$0.30	36.67
Avita Medical	$71.61 million	5.74	-$48.59 million	($1.44)	-9.28

Ambu A/S has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Ambu A/S, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ambu A/S has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Avita Medical has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.

Profitability

This table compares Ambu A/S and Avita Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ambu A/S	8.18%	8.49%	6.75%
Avita Medical	-56.96%	N/A	-78.53%

Insider and Institutional Ownership

27.7% of Avita Medical shares are owned by institutional investors. 2.2% of Avita Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Ambu A/S and Avita Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ambu A/S	0	1	0	0	2.00
Avita Medical	1	1	5	0	2.57

Avita Medical has a consensus price target of $12.20, suggesting a potential downside of 8.68%. Given Avita Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Avita Medical is more favorable than Ambu A/S.

About Ambu A/S

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. The company was founded in 1937 and is headquartered in Ballerup, Denmark.

About Avita Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.